Gilead Sciences, Inc.: Gilead Sciences to Acquire MYR GmbH Gilead to Acquire Hepcludex
, a First-in-Class Entry Inhibitor, for Treatment of Chronic Hepatitis Delta Virus (HDV), Adding Immediate Revenue After Closing of Transaction
- Hepcludex Was Conditionally Approved in Europe in July 2020 Based on Phase 2 Data and Submission for Accelerated Approval in United States is Anticipated in Second Half of 2021
Acquisition Builds on Gilead s Strength as a Global Leader in Virology and Liver Diseases with Addition of First Marketed Product for Treatment of HDV
Gilead Sciences, Inc. (Nasdaq: GILD) and MYR GmbH, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus (HDV), today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MYR for approximately €1.15 billion in cash, payable upon closing of the transaction plus a potential fut
Gilead Sciences to Acquire MYR GmbH - MarketWatch marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.